Navigation Links
Former CMS Administrator: "'Blunt Instrument' Policies an Increasingly Bad Fit in Era of Personalized Health Care"
Date:5/16/2008

McClellan questions "current pathway of short term patches" in health care

policy reform

ORLANDO, Fla., May 16 /PRNewswire-FirstCall/ -- Recent legislative emphasis on price negotiation and physician reimbursement as a means to reduce health care costs are nothing more than "short term patches" that hold no potential for truly reforming health care, former Centers for Medicare and Medicaid Services (CMS) Administrator Dr. Mark McClellan told hundreds of health care decision makers today in delivering the keynote address at Medco Health Solutions, Inc. (NYSE: MHS) 2008 Drug Trend "Predictions" Symposium.

"We don't seem to be making much progress politically; it's easy to be cynical when it comes to health care," said McClellan, current Director of the Engelberg Center for Health Care Reform and Senior Fellow at the Brookings Institute. "Just focusing on cost reduction doesn't do much to solve the problem of getting more value for what we are spending."

McClellan characterized as unsustainable short-term strategies such as across-the-board reductions in Medicare reimbursement fees for physicians and coverage policies that prevent access to the latest biomedical technologies; yet indicated a shift is clearly afoot within both political parties as candidates move towards a value-based, quality-focused approach to improving care for millions of Americans.

"There simply isn't any additional funding available for new health care programs, but this presents the foundation for changing health care," said McClellan. "Each of the political candidates is demonstrating a new emphasis on improving quality and efficiency of care."

McClellan highlighted improved management of chronic diseases and complications; improved identification of patients at risk for chronic diseases; an increased focus on wellness; and better support for navigation of the health care system as strategies espoused by both parties that have the potential to improve quality of care.

"Both party's candidates are placing a greater emphasis than ever before on strategies like chronic disease prevention and healthcare information technology," said McClellan.

McClellan commented on additional issues facing the current and future health care landscape:

-- Recent rapid advancements in gene-based care such as proteomics and

genomics, RNA interference, regenerative medicine and epigenetics are

ushering in the "Biomedical Century" and introducing a sea change in

personalized medicine that makes "all the spending worth it."

-- A key driver of cost is not rising prices or an aging population; in

fact, the key driver is simply more people getting more treatments

combined with longer life expectancy. However, there is a major

problem with the underuse of services for chronic disease management,

as patients with chronic diseases get appropriate treatment only about

55 percent of the time.

-- While the introduction of biosimilars holds tremendous promise for

financial relief, it is unlikely that Congress will act on legislation

this year to advance the policies around the emerging therapeutic

category. McClellan also noted that the Food and Drug Administration

makes a clear distinction between generic similars and interchangeables

in oral medications, a distinction that will prove to be inapplicable

to biologics and could present unique challenges in crafting

appropriate legislation.

About Medco

Medco Health Solutions, Inc., (NYSE: MHS) is the nation's leading pharmacy benefit manager based on its 2007 total net revenues of more than $44 billion. Medco's prescription drug benefit programs, covering approximately one-in-five Americans, are designed to drive down the cost of pharmacy health care for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program and those served by its specialty pharmacy segment, Accredo Health Group. Medco, the world's most advanced pharmacy(TM), is positioned to serve the unique needs of patients with chronic and complex conditions through its Medco Therapeutic Resource Centers(R), including its enhanced diabetes pharmacy care practice through the Liberty acquisition. Medco is the highest-ranked independent pharmacy benefit manager on the 2008 Fortune 100 list. On the Net: http://www.medco.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward- looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Medco Health Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Retired Supreme Court Justice Sandra Day OConnor and Former House Speaker Newt Gingrich Address Senate Special Committee on Aging, Calling for Urgent Action Against Alzheimers Disease
2. Former GE, Kodak and SGS Executive Dan Kerpelman to Join Bio-Optronics as President and CEO
3. SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility
4. Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group
5. Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico
6. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
7. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
8. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
9. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
10. Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility
11. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... New Orleans, La. (PRWEB) , ... March 23, ... ... of real-time, industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” ... for APMT customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s ...
(Date:3/22/2017)... -- Good Start Genetics, a leading family genomics company, ... covered lives mark through its most recent payor addition, ... . With newly signed contracts nationally and others in ... acceptance based on the quality of its science, the ... industry-leading customer care and support and its published cost-effectiveness ...
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT ... (the "Company" or "Propellon"), a start-up created by ... anti-cancer therapeutics. FACIT,s investment, combined with non-dilutive capital, ... program. The seed funding enables Propellon to accelerate ... the Company for financing and/or entering a strategic ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
Breaking Biology News(10 mins):